In case of patients with comorbidities (obesity, diabetes, hypertension) or dysregulated immunity, the treatment regimen could further include antiinflammatory drugs (e.g., anti-IL6/anti-IL6R) and RAS inhibitors and hrACE2 for the diabetic patients, in particular. This evidence concerns the gene IL6 and obesity due to melanocortin 4 receptor deficiency.